Patents by Inventor Jérôme TOUM

Jérôme TOUM has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHENOL RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF
    Publication number: 20240285614
    Abstract: Provided herein are compounds and methods for the treatment of cancer. The methods include administering to a subject in need a therapeutically effective amount of a cyclic sulfonamide RNR inhibitor disclosed herein.
    Type: Application
    Filed: February 6, 2024
    Publication date: August 29, 2024
    Inventors: Anthony B. PINKERTON, Jacques MAUGER, Yen Pham Hong TRUONG, Camille REMEUR, Jérôme TOUM, Olivier MIRGUET
  • Prodrug of 1,1?-(1,6-dioxo-1,6-hexanediyl)bis-D-proline
    Patent number: 10597385
    Abstract: The present invention relates to the compound (2R,2?R)-bis(((((tetrahydro-2H-pyran-4-yl)oxy)carbonyl)oxy)methyl) 1,1?-adipoylbis(pyrrolidine-2-carboxylate), pharmaceutical compositions comprising the same and the use of the same for treatment of diseases or disorders wherein depletion of serum amyloid P component (SAP) would be beneficial, including amyloidosis, Alzheimer's disease, type 2 diabetes mellitus and osteoarthritis.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: March 24, 2020
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Alexis Denis, Olivier Mirguet, Jérôme Toum
  • D-proline derivatives as SAP depleting agent
    Patent number: 10328052
    Abstract: The present invention relates to the compound ((2R,2?R)-bis(((tetrahydro-2H-pyran-4-carbonyl)oxy)methyl) 1,1?-adipoylbis(pyrrolidine-2-carboxylate), pharmaceutical compositions comprising the same and the use of the same for treatment of diseases or disorders wherein depletion of serum amyloid P component (SAP) would be beneficial, including amyloidosis, Alzheimer's disease, type 2 diabetes mellitus and osteoarthritis.
    Type: Grant
    Filed: October 25, 2016
    Date of Patent: June 25, 2019
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Alexis Denis, Olivier Mirguet, Jérôme Toum
  • D-PROLINE DERIVATIVES AS SAP DEPLETING AGENT
    Publication number: 20190060274
    Abstract: The present invention relates to the compound ((2R,2?R)-bis(((tetrahydro-2H-pyran-4-carbonyl)oxy)methyl) 1,1?-adipoylbis(pyrrolidine-2-carboxylate), pharmaceutical compositions comprising the same and the use of the same for treatment of diseases or disorders wherein depletion of serum amyloid P component (SAP) would be beneficial, including amyloidosis, Alzheimer's disease, type 2 diabetes mellitus and osteoarthritis.
    Type: Application
    Filed: October 25, 2016
    Publication date: February 28, 2019
    Inventors: Alexis DENIS, Olivier MIRGUET, Jérôme TOUM
  • PRODRUG OF 1,1'-(1,6-DIOXO-1,6-HEXANEDIYL)BIS-D-PROLINE
    Publication number: 20180099955
    Abstract: The present invention relates to the compound (2R,2?R)-bis(((((tetrahydro-2H-pyran-4-yl)oxy)carbonyl)oxy)methyl) 1,1?-adipoylbis(pyrrolidine-2-carboxylate), pharmaceutical compositions comprising the same and the use of the same for treatment of diseases or disorders wherein depletion of serum amyloid P component (SAP) would be beneficial, including amyloidosis, Alzheimer's disease, type 2 diabetes mellitus and osteoarthritis.
    Type: Application
    Filed: December 11, 2017
    Publication date: April 12, 2018
    Inventors: Alexis Denis, Olivier Mirguet, Jérôme Toum
  • Prodrug of 1,1?-(1,6-dioxo -1,6-hexanediyl)bis-D-proline
    Patent number: 9873686
    Abstract: The present invention relates to the compound (2R,2?R)-bis(((((tetrahydro-2H-pyran-4-yl)oxy)carbonyl)oxy)methyl) 1,1?-adipoylbis(pyrrolidine-2-carboxylate), pharmaceutical compositions comprising the same and the use of the same for treatment of diseases or disorders wherein depletion of serum amyloid P component (SAP) would be beneficial, including amyloidosis, Alzheimer's disease, type 2 diabetes mellitus and osteoarthritis.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: January 23, 2018
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Alexis Denis, Olivier Mirguet, Jérôme Toum
  • PRODRUG OF 1,1'-(1,6-DIOXO-1,6-HEXANEDIYL)BIS-D-PROLINE
    Publication number: 20170267665
    Abstract: The present invention relates to the compound (2R,2?R)-bis(((((tetrahydro-2H-pyran-4-yl)oxy)carbonyl)oxy)methyl) 1,1?-adipoylbis(pyrrolidine-2-carboxylate), pharmaceutical compositions comprising the same and the use of the same for treatment of diseases or disorders wherein depletion of serum amyloid P component (SAP) would be beneficial, including amyloidosis, Alzheimer's disease, type 2 diabetes mellitus and osteoarthritis.
    Type: Application
    Filed: June 1, 2017
    Publication date: September 21, 2017
    Inventors: Alexis DENIS, Olivier MIRGUET, Jérôme TOUM
  • Prodrug of 1,1?-(1,6-dioxo-1,6-hexanediyl)bis-D-proline
    Patent number: 9737505
    Abstract: The compound (2R,2?R)-bis(((((tetrahydro-2H-pyran-4-yl)oxy)carbonyl)oxy)methyl) 1,1?-adipoylbis(pyrrolidine-2-carboxylate) possesses physicochemical properties suitable for pharmaceutical development and is capable of generating (R)-1-[6-[(R)-2-carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl]pyrrolidine-2-carboxylic acid (CPHPC) in quantities capable of depleting serum amyloid P component (SAP) efficiently following oral administration, making it useful in the treatment of amyloidosis, Alzheimer's disease, type 2 diabetes mellitus and osteoarthritis.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: August 22, 2017
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Alexis Denis, Olivier Mirguet, Jérôme Toum
  • Prodrug of 1,1?-(1,6-dioxo-1,6-hexanediyl)bis-D-proline
    Patent number: 9701668
    Abstract: The present invention relates to the compound (2R,2?R)-bis(((((tetrahydro-2H-pyran-4-yl)oxy)carbonyl)oxy)methyl) 1,1?-adipoylbis(pyrrolidine-2-carboxylate) of formula (I), pharmaceutical compositions comprising the same and the use of the same for treatment of diseases or disorders wherein depletion of serum amyloid P component (SAP) would be beneficial, including amyloidosis, Alzheimer's disease, type 2 diabetes mellitus and osteoarthritis.
    Type: Grant
    Filed: April 27, 2015
    Date of Patent: July 11, 2017
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Alexis Denis, Olivier Mirguet, Jérôme Toum
  • PRODRUG OF 1,1'-(1,6-DIOXO-1,6-HEXANEDIYL)BIS-D-PROLINE
    Publication number: 20160081983
    Abstract: The present invention relates to the compound (2R,2?R)-bis(((((tetrahydro-2H-pyran-4-yl)oxy)carbonyl)oxy)methyl) 1,1?-adipoylbis(pyrrolidine-2-carboxylate), pharmaceutical compositions comprising the same and the use of the same for treatment of diseases or disorders wherein depletion of serum amyloid P component (SAP) would be beneficial, including amyloidosis, Alzheimer's disease, type 2 diabetes mellitus and osteoarthritis.
    Type: Application
    Filed: October 28, 2015
    Publication date: March 24, 2016
    Inventors: Alexis DENIS, Olivier Mirguet, Jérôme Toum
  • A PRODRUG OF 1,1'-(1,6-DIOXO-1,6-HEXANEDIYL)BIS-D-PROLINE
    Publication number: 20160075694
    Abstract: The present invention relates to the compound (2R,2?R)-bis(((((tetrahydro-2H-pyran-4-yl)oxy)carbonyl)oxy)methyl) 1,1?-adipoylbis(pyrrolidine-2-carboxylate) of formula (I), pharmaceutical compositions comprising the same and the use of the same for treatment of diseases or disorders wherein depletion of serum amyloid P component (SAP) would be beneficial, including amyloidosis, Alzheimer's disease, type 2 diabetes mellitus and osteoarthritis.
    Type: Application
    Filed: April 27, 2015
    Publication date: March 17, 2016
    Inventors: Alexis DENIS, Olivier MIRGUET, Jérôme TOUM